Vogelzang Highlights Decades of Innovation in Prostate Cancer

Brittany Lovely
Published: Monday, Aug 12, 2019
Nicholas J. Vogelzang, MD

Nicholas J. Vogelzang, MD

The past 20 years have witnessed a wide range of changes affecting the treatment of patients with prostate cancer. Classification of disease, genomic profiling, chemotherapy regimens, and surgical improvements have improved outcomes for patients and provided clinicians with numerous options for treatment. “It’s been amazing to see the advances that have really revolutionized the field of prostate cancer care,” said Nicholas J. Vogelzang, MD, FASCO, FACP, associate chair of the Genitourinary (GU) Committee for US Oncology Research and vice chair of the GU Committee for SWOG, a worldwide network of investigators who design clinical trials.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication